Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

123.19 -0.60 (-0.48%)
Streaming Delayed Price Updated: 11:31 AM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
51 52 Next >
Vasculitis Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examines DelveInsight | Key Companies – Novartis, Ambulero, InflaRx
Continue reading "Vasculitis Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examines DelveInsight | Key Companies – Novartis, Ambulero, InflaRx" 
Via Get News
5 Value Stocks In The Healthcare Sector
What are Value Stocks? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators... 
Via Benzinga
Top Financial Media Stories Thursday, September 15: US Railway Companies, Unions Reach Tentative Agreement, Tesla To Wind Down Stores In China's Flashy Malls, Netflix Could Face Legal Action Over South Korean Crime Drama And More..
US Railway Companies, Unions Reach Tentative Agreement Averting Catastrophic Strike 
Via Benzinga
Swiss Competition Commission Investigates Novartis' Patent Use To Fend Off Competition
The Swiss competition commission (COMCO) has initiated an investigation against Novartis AG (NYSE: NVS) over the alleged unlawful patent use to reduce competitive pressure.  
Via Benzinga
Novartis' Cosentyx Shows To Ease Symptoms In Painful Skin Condition
 
Via Benzinga
Novartis Injects $300M In Early-Stage Biologics Research Tech
 
Via Benzinga
Novartis' Kisqali Adds One More Year Of Survival Benefit In Breast Cancer Setting
 
Via Benzinga
Novartis Dodges Whistleblower Lawsuit Regarding Multiple Sclerosis Drug Kickback Claims
A federal judge dismissed a whistleblower lawsuit accusing Novartis AG (NYSE: NVS) of paying doctors kickbacks at "sham" speaker programs to boost prescriptions of its multiple sclerosis blockbuster... 
Via Benzinga
A Major October Catalyst Could Make This Eye Stock A Ten Bagger, Analyst Says
Chardan initiated coverage on Outlook Therapeutics Inc (NASDAQ: OTLK) with a Buy rati 
Via Benzinga
5 Value Stocks In The Healthcare Sector
What are Value Stocks? 
Via Benzinga
Smart Manufacturing Market Share 2022 Size, Key Trends, Future Scope, Global Outlook, Investment Plans and Development Status by 2027
Smart Manufacturing Market 2022 | Major Key Players included in this Report are Pfizer , Novartis, Abbott Laboratories and Many More with SWOT Analysis by 2027 
Via SBWire
VideoKrtoon Offers State Of The Art 2D Animation Services
Via Prodigy
Novartis To Spinoff Sandoz Business To Create #1 European Generics Company
 
Via Benzinga
Novartis' Lung Cancer Candidate Misses Primary Goal In Post Surgery Setting
 
Via Benzinga
No Early Relief for JW Therapeutics from Cancer Wonder Drug
Key Takeaways: JW Therapeutics prices its new cancer therapy at around a million yuan, with the high production costs hard to bring down.  Large-scale market expansion is not going to be easy  The... 
Via Benzinga
Appointment of Sachin Nanavati to PreveCeutical's Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - September 6, 2022) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company"... 
Via Newsfile
SiO2 Materials Science Names Yves Steffen as Chief Executive Officer
SiO2 Materials Science today announced the Board of Directors has appointed Yves Steffen as CEO effective Aug. 1, 2022. 
Via Newswire.com
Top Financial Stories Thursday, September 1: Netflix Weighs Charging High Sum For Ads, Self Harm posts Grow On Twitter, California Fast-Food Bill Faces Industry Backlash...
Wall Street Journal 
Via Benzinga
Novartis Appoints Merck Executive As Research Head
 
Via Benzinga
NYSE:NVS Investor Alert: Investigation over Potential Wrongdoing at Novartis AG
San Diego, CA -- (SBWIRE) -- 08/30/2022 -- An investigation was announced over potential breaches of fiduciary duties by certain directors at Novartis AG. 
Via SBWire
Novartis' Scemblix Snags European Approval For Chronic Myeloid Leukemia
 
Via Benzinga
With Sandoz Spinoff, Novartis Slams Brakes On Huntington's Trial
Novartis AG (NYSE: NVS) suspended dosing in a Huntington's disease study because early signs of side effects were seen in some participants in the trial. 
Via Benzinga
Benzinga Before The Bell: Twitter Whistleblower Peiter Zatko To Depose Before Senate Panel, GameStop To Boost Employee Compensation To Drive Growth, California Proposes Total Ban On New Gasoline Car Sales By 2035 And Other Top Financial Stories Thursday,
Reuters Stuck By Chip Shortage, Stellantis Halts Production In Sochaux Plant 
Via Benzinga
Aerie Pharmaceuticals (NASDAQ: AERI) Enters into Agreement to be Acquired by Alcon (NYSE: ALC) for $770 Million
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) is engaged within the research, development and commercialization of ophthalmic therapies for the treatment of 
Via Spotlight Growth
Caribou's Blood Cancer Candidate Shows Response Rates Better Than Novartis,' This Analyst Writes
 
Via Benzinga
Emery Pharma Announces New Biologics Analytical Division
Supporting end-to-end research and development of large molecule drugs including, biologics, antibody-drug conjugates, biosimilars, and more 
Via Newswire.com
A Look Into Healthcare Sector Value Stocks
  Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base... 
Via Benzinga
The Most Expensive Drug From Novartis Associated With Two Deaths: Report
Two children with spinal muscular atrophy have died after receiving Novartis AG's (NYSE: NVS) Zolgensma, a one-time gene therapy, spotlighting its risks and questioning the safety of genetic medicines... 
Via Benzinga
This Nasal Spray For Eye Disease Stock Is 'Attractive', Has Potential 160% Upside
 
Via Benzinga
NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) Pioneering Innovative Hypertension Treatments
Via Investor Brand Network
Topics Intellectual Property
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
51 52 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.